Treatment Details – 3.2 months
|Patients: This Phase II study involved 14 patients with malignant pleural mesothelioma. Eleven patients were men, and three were women. The median age was 59.5 years. All patients received at least one chemotherapeutic treatment before this study. Eight patients had been exposed to asbestos.|
Treatment: The treatment consisted of two chemotherapeutic agents: Raltitrexed and Oxaliplatin.
Toxicities: No grade 4 toxicities were observed. Grade 3 toxicities included asthenia, anemia, neutropenia, nausea, paresthesia, and transaminase elevation.
Results: There were no responses and the median survival was 3.2 months (14 weeks). The trial was stopped because there was no beneficial response to treatment.
Correspondence: Camillo Porta, MD